荣昌生物获上百家机构调研,关注其核心管线开发进展。RC18、RC48国内外研发进展顺利,涉及多个治疗领域,公司财务状况有所改善,净亏损同比缩小。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.